BioFocus has enhanced its screening library through new compound supply agreements with InterBioScreen, Enamine and ChemBridge. BioFocus now offers screening platforms with more than 900,000 unique chemical compounds and approximately 100,000 probes from natural sources.
 
Under the agreements, BioFocus has selected a total of 350,000 new compounds, which will replace a portion of the current screening library, increasing novelty, structural diversity and lead likeness, as well as the overall solubility profile.
 
“Integrating our screening collection with our assay expertise has provided our clients with a platform that has the size and flexibility to deliver on their hit-finding campaigns,” said Kate Hilyard, vice president Biological Sciences BioFocus. ”This latest round of compound acquisition demonstrates our commitment to maintaining our reputation as a leading partner in drug discovery.”